A type B hemophiliac treatment acquired the selling approval after the launch of the Benefix 10 years ago

A competing product of the only type B hemophiliac treatment launched in Korea, Benefix, is expected to be launched.

It has been 10 years since the launch of Benefix.

On the 6^th, the Ministry of Food and Drug Safety approved the selling rights of the Baxter’s Rixubis

The type B hemophilia is the second most common hemophilia after the type A.

Currently, the only type B hemophiliac treatment...